GLP-1s after cancer: Who needs a different risk threshold?

GLP-1 drugs are now a part of routine medical care. A nationally representative KFF poll conducted in late 2025 found that 12% of US adults were taking one, double the proportion reported 18 months earlier.^[]

Cancer survivorship clinics are seeing similar uptake. An analysis of 2024 National Health Interview Survey data, presented at the 2026 ASCO Annual Meeting, estimated injectable GLP-1 use at 21.2% among US cancer survivors with diabetes.^[] Use reached 27.6% among survivors with obesity.

Is a GLP-1 safe for cancer survivors?

Board-certified urologist Dr. Arthur Burnett II, MD, says, “A history of cancer doesn’t automatically mean someone can’t take a GLP-1 medication. Every patient deserves an individualized conversation.”

“Many cancer survivors are also dealing with obesity, diabetes, heart disease, or other chronic conditions that can have a major impact on their long-term health. If a GLP-1 medication can help improve those conditions, it may be an appropriate option,” he adds.

Current evidence has not shown an overall increase in cancer incidence with GLP-1 receptor agonists. Several observational analyses instead associate treatment with lower rates of obesity-related cancers.^[]

At the 2026 ASCO Annual Meeting, a retrospective study of 12,112 patients with stage I to III obesity-related cancers found less progression to stage IV disease among GLP-1 users than matched DPP-4 inhibitor (gliptin) users.^[] Relative reductions included 50% for non-small cell lung cancer, 43% for breast cancer, 38% for liver cancer, and 31% for colorectal cancer. These associations do not prove a treatment effect. 

Separate real-world breast cancer data presented in 2026 linked GLP-1 therapy with lower breast cancer incidence after adjustment for BMI, diabetes, breast density, race, age, and ethnicity.^[]

Dr. Burnett adds, “The key is understanding the whole picture: what type of cancer they had, whether they’re in remission, what treatments they received, and how they’re doing today. We shouldn’t let a cancer diagnosis from years ago be the only factor driving the decision.”

The survivor is not a typical weight-loss patient

Although GLP-1 therapies reduce fat mass, lean tissue also accounts for an estimated 26%–40% of total weight lost in several body-composition studies.^[]

According to Dr. Burnett, “Some survivors continue to struggle with chronic digestive problems, poor appetite, weight loss, or difficulty getting enough nutrition because of surgery, chemotherapy, or radiation. Since GLP-1 medications can reduce appetite and cause nausea or other gastrointestinal side effects, those issues deserve careful consideration.” 

“If we decide a GLP-1 medication is appropriate, I also want to make sure we’re protecting muscle through adequate protein, physical activity—especially resistance training when possible—and good nutritional support. The goal isn’t simply to weigh less; It’s to be healthier and stronger,” Dr. Burnett adds.

Cancer-specific exclusions are still applicable 

Sera Ramadan, DO, double board-certified in internal medicine and obesity medicine, says, “Any history suggestive of medullary thyroid carcinoma or MEN type 2 is an absolute contraindication. Beyond this, caution is warranted in patients with severe sarcopenia, as approximately 20%–30% of GLP-1 RA-induced weight loss may come from lean mass.” 

The FDA contraindicates semaglutide in patients with a personal or family history of medullary thyroid carcinoma or MEN2.^[] However, the warning does not extend to other thyroid cancer variants such as papillary or follicular thyroid cancer. 

“Patients with clinically significant gastroparesis or difficulty tolerating oral intake should also be approached cautiously, as GLP-1 RAs delay gastric emptying and can exacerbate these symptoms. Additionally, patients with GLP-1R-high neuroendocrine tumors warrant careful consideration before initiating therapy,” Dr. Ramadan adds.

Current FDA prescribing information warns about acute pancreatitis and severe gastrointestinal reactions and does not recommend semaglutide in patients with severe gastroparesis.^[]

Benefits

“Obesity itself is a risk factor for at least 13 obesity-associated cancers, so treating obesity may still confer benefit even in complex patients,” Dr. Ramadan says.

These include endometrial, esophageal, upper stomach, liver, kidney, pancreatic, colorectal, gallbladder, postmenopausal breast, ovarian, and thyroid cancers, as well as multiple myeloma and meningioma, according to the National Cancer Institute.^[]

“Emerging data suggest that GLP-1 RA exposure after cancer diagnosis may be associated with reduced metastatic progression across multiple solid tumors, and improved outcomes in breast cancer survivors compared with bariatric surgery alone. However, these findings are observational, and prospective randomized trials are needed to confirm causality and establish the role of GLP-1 RAs in cancer survivorship,” Dr. Ramadan adds.

Two retrospective studies support these observations. A 2026 ASCO analysis linked GLP-1 RA exposure after diagnosis with reduced metastatic progression across several solid tumors.^[]

A separate Annals of Surgery study found better survival and lower locoregional recurrence with GLP-1 RAs than with bariatric surgery among postmenopausal women with obesity and stage 0 to III breast cancer.^[]

Dr. Ramadan, however, warns regarding the effects of GLP-1 RAs on coadministered oral medications. “The primary mechanism is delayed gastric emptying, which reduces peak drug concentrations and delays time to peak concentration, rather than decreased overall absorption,” she says. 

“For patients on oral anti-cancer therapies such as anti-estrogen agents or oral chemotherapy, this pharmacokinetic alteration should be discussed between the obesity medicine specialist and the oncologist, particularly for drugs with a narrow therapeutic index,” she explains. “If a patient is experiencing significant vomiting, the concern extends beyond pharmacokinetics to actual medication loss, which further underscores the need for close interdisciplinary communication.”